Interestingly, in colorectal cancer and melanoma, enhanced anti-PD-1 efficacy could be achieved by depletion of METTL3 and METTL14, potentially via increased CD8+ T-cell infiltration and tumor killing function [288]. Here, METTL14 is linked to neoplasm.